# PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

> **NCT05553834** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Duke University** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **COMBINATION_PRODUCT:** Alirocumab and Cemiplimab

## Key facts

- **NCT ID:** NCT05553834
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-16
- **Primary completion:** 2025-09-16
- **Final completion:** 2026-11-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553834, "PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05553834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*